Evidence map›Paper›PMID 40874510›Full record

ArticleJournal of cellular and molecular medicine2025

A Comparison of Novel Serum Markers of Liver Health in Adolescents With Metabolic Dysfunction-Associated Steatotic Liver Disease.

Neeharika Bade, Diana A Hellman, David J Matye, Shaoning Jiang, Jeanie B Tryggestad, Zhongxin Yu, Kevin R Short, Sirish K Palle

Abstract readComparative Study
In one paragraph

Article in Journal of cellular and molecular medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Unifying and unique roles of non-coding RNA biomarkers in liver and heart fibrosis.Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2026
    Review
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Neeharika BadeSection of Gastroenterology, Hepatology, and Nutrition, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, USA.
Diana A HellmanSection of Diabetes and Endocrinology, Department of Pediatrics, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, USA.
David J MatyeDepartment of Pharmacology, Toxicology and Therapeutics, University of Kansas Medical Center, Kansas City, Kansas, USA.
Shaoning JiangSection of Diabetes and Endocrinology, Department of Pediatrics, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, USA.
Jeanie B TryggestadSection of Diabetes and Endocrinology, Department of Pediatrics, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, USA.
Zhongxin YuDepartment of Pathology, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, USA.
Kevin R ShortSection of Diabetes and Endocrinology, Department of Pediatrics, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, USA.
Sirish K PalleSection of Gastroenterology, Hepatology, and Nutrition, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, USA.ORCID 0000-0002-6687-5040

Funding

Tracking and Evaluation CoreU54GM104938 · NIGMS · UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR · PI PAUL G SPICER · 2013 to 2026
$68.2M
NIGMS NIH HHS U54 GM104938NIGMS NIH HHS U54GM104938Oklahoma Children's Health FoundationPaediatric Endocrine SocietyUniversity of Oklahoma Paediatric Metabolic Research ProgramU.S. Department of Health and Human Services > National Institutes of Health
6 · The paper itself

Abstract

Several non-invasive biomarkers for paediatric metabolic dysfunction-associated steatotic liver disease (MASLD) have been reported, but no prior studies directly compared multiple protein or microRNA (miRNA) markers of liver health in adolescents with and without MASLD and determined which serum markers are associated with liver histopathological features. We measured 6 serum protein and 4 miRNA candidates in 3 groups of participants: 23 with obesity and biopsy-proven MASLD, 24 controls with obesity (Ob) and 24 controls with normal weight (NW). The MASLD group had higher median values for cytokeratin 18 (CK-18, 8.5 and 5.6-fold higher than NW and Ob, respectively), CK-18 fragments (2.6- and 2.6-fold), collagen IV (0.9- and 0.6-fold), miR-122 (16.9- and 10.7-fold) and miR-192 (9.7- and 12.0-fold). YKL-40 and N-terminal propeptide of type III procollagen were only higher in the MASLD group compared to the NW group. Serum AST, CK-18, CK-18 fragments, miR-122 and miR-192 were positively correlated with liver fibrosis stage. Area under the receiver operating curve for identifying MASLD for CK-18 (0.962), miR-192 (0.945) and miR-122 (0.944) was higher than ALT (0.935). miR-122 in serum and liver was inversely correlated in MASLD patients but neither was associated with putative mRNA targets AGPAT1 and DGAT1. These results show that CK-18, miR-122 and miR-192 are marginally better predictors of MASLD than ALT and correlated with fibrosis in this cohort, supporting further work to confirm these findings.

Indexed as

BiomarkersFatty LiverLiverAdolescentCase-Control StudiesChildFemaleHumansKeratin-18MaleMicroRNAsROC CurveBiomarkersKeratin-18MicroRNAsMIRN122 microRNA, humanfibrosisMASLDmicroRNAobesitypaediatric

Identifiers

PMID40874510
PMCPMC12392135

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.